The ssPalmE formulation was significantly more effective than ssPalmM, where Myristic acid was the hydrophobic scaffold, suggesting that α-TOS worked synergistically with the VEGFR agonist against renal cell carcinoma in vivo [77]. This evidence concerns the gene KDR and hereditary clear cell renal cell carcinoma.